金吾财讯 | 据外媒报道，礼来（LLY）CEO戴夫·里克斯（Dave Ricks）受访时表示，自7月美国联邦医保Medicare开启肥胖症药物保障以来，已有70万名老年新患者启用GLP-1类药物，其中70%的患者选择礼来的产品。里克斯评价这项保障计划推进情况“十分鼓舞人心”，认为这正是GLP-1大市场扩容所期待的局面。该数据直观体现Medicare医保落地对药物可及性的提升，也反映礼来和主要对手诺和诺德在新增患者争夺中的竞争格局。本次药物保障依托临时项目Bridge，符合资格受益人每月仅需自付50美元即可购买减重药。这项联邦医保面向65岁及以上人群或残障人士，覆盖规模约6600万人。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.